TY - JOUR
T1 - ROCK inhibitors for the treatment of ocular diseases
AU - Nourinia, Ramin
AU - Nakao, Shintaro
AU - Zandi, Souska
AU - Safi, Sare
AU - Hafezi-Moghadam, Ali
AU - Ahmadieh, Hamid
N1 - Publisher Copyright:
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved.
PY - 2018
Y1 - 2018
N2 - The Rho-kinase/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.
AB - The Rho-kinase/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.
UR - http://www.scopus.com/inward/record.url?scp=85058363185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058363185&partnerID=8YFLogxK
U2 - 10.1136/bjophthalmol-2017-310378
DO - 10.1136/bjophthalmol-2017-310378
M3 - Review article
AN - SCOPUS:85058363185
SN - 0007-1161
VL - 102
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
IS - 1
ER -
